Search

everythinglearnresearchcommunity

for

Search:↓

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

Biomedical engineers are crucial for developing better treatments for chronic and autoimmune diseases.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Obesity is linked to various skin disorders, which can help with early diagnosis and prevention of long-term health issues.

Most skin conditions can be managed with general medical knowledge.

Hair loss in men may be caused by inflammation triggered by hormones, and treatments reducing inflammation could potentially promote hair growth.

Nanovesicles improve drug delivery through the skin, offering better treatment outcomes and fewer side effects.

Nanoemulgel improves delivery and effectiveness of plant-based drugs for various conditions.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

Good nutrition is crucial for health and preventing disease, and supplements can help prevent nutrient deficiencies.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Oral propranolol successfully treated a baby's skin growth and ulceration linked to PELVIS syndrome.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Laser device increases hair density, safe for treating hair loss in men and women.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

New alopecia treatments aim for better results and fewer side effects.

Some alternative treatments for hair loss might work, but more research is needed.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

The treatment helped reduce symptoms and stabilize the hairline in most patients with Frontal Fibrosing Alopecia, but hair regrowth was limited.

Methotrexate reduced the need for steroids in asthma patients without worsening their condition.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

A patient with complete hair loss regrew all her hair using tofacitinib.